Brookline Capital Management Predicts Kura Oncology FY2029 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Equities research analysts at Brookline Capital Management issued their FY2029 earnings estimates for Kura Oncology in a report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann anticipates that the company will earn $12.19 per share for the year. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Other analysts have also issued research reports about the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. JMP Securities reiterated a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research note on Tuesday, November 19th. UBS Group initiated coverage on shares of Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price for the company. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Finally, Stifel Nicolaus cut shares of Kura Oncology from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $27.38.

Kura Oncology Trading Down 4.8 %

Shares of KURA stock opened at $7.78 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The company has a market cap of $605.00 million, a price-to-earnings ratio of -3.30 and a beta of 0.81. Kura Oncology has a 1 year low of $7.70 and a 1 year high of $24.17. The firm has a fifty day moving average price of $12.11 and a 200-day moving average price of $17.08.

Institutional Trading of Kura Oncology

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sofinnova Investments Inc. grew its position in shares of Kura Oncology by 64.4% during the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after purchasing an additional 323,303 shares in the last quarter. Armistice Capital LLC boosted its stake in Kura Oncology by 14.7% during the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after buying an additional 302,000 shares during the last quarter. HighVista Strategies LLC bought a new position in Kura Oncology during the second quarter valued at approximately $345,000. Alethea Capital Management LLC grew its holdings in Kura Oncology by 2.4% during the 2nd quarter. Alethea Capital Management LLC now owns 265,906 shares of the company’s stock valued at $5,475,000 after buying an additional 6,300 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in Kura Oncology by 251.5% in the 2nd quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock worth $1,681,000 after acquiring an additional 58,422 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.